Pharmacy

When combined with immunotherapy, an mRNA-based vaccine has been found to cut the risk of melanoma recurrence and distant metastasis more than immunotherapy alone. Results from the phase 3 trial of the vaccine, called intismeran, will be presented at an…

AstraZeneca has ended a phase 3 clinical trial of the drug volrustomig for the treatment of metastatic non-small cell lung cancer. The trial was specifically evaluating the drug in combination with chemotherapy compared to pembrolizumab and chemotherapy in metastatic non-small…

The FDA has granted accelerated approval to Bristol Myers Squibb’s Zenbexus, the first FDA-approved cereblon E3 ligase modulator, or CELMoD, a new class of treatment for multiple myeloma. Zenbexus (iberdomide), in combination with daratumumab and hyaluronidase-fihj and dexamethasone, was approved…

About 1 in 5 second-level appeals of denied anticancer medications in Medicare Part D were overturned, according to a study published July 23 in JAMA Network Open. Researchers analyzed 4,952 second-level appeals from 2020 to 2024. Here are four things…

The FDA has rejected a radiopharmaceutical therapy from ITM Isotope Technologies Munich that was positioned to compete with Novartis’ leading treatments in the space. The agency issued a complete response letter for ITM-11, also known as 177Lu-edotreotide, saying it cannot…